Home / Events / 2022 NRDL Pricing Implications and Access Outcomes


2022 NRDL Pricing Implications and Access Outcomes

Available On Demand

What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access?

The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies.

In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an in-depth analysis of the 2022 NRDL and key trends from previous NRDL negotiations. We will discuss the pricing implications and evidence strategies needed to secure public funding in China, along with how to navigate key NRDL strategies.

Key Webinar Topics:

  • Introduction to NRDL and China access landscape overview
  • Key updates in 2022 NRDL
  • Case studies of oncology, rare disease and chronic disease drugs


Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.